Table 2.
Ofloxacin 2·0 μg/mL susceptibility testing results
| Azerbaijan | Bangladesh | Belarus (Minsk city) | Pakistan | South Africa (Gauteng) | South Africa (Kwazulu Natal) | |
|---|---|---|---|---|---|---|
| New tuberculosis cases | 528, 3·4% (1·9–5·0) | 736, 4·4% (2·6–6·2) | 141, 7·0% (2·7–11·3) | 1301, 11·2% (7·8–14·7) | 716, 1·0% (0·1–1·8) | 437, 1·0% (0·0–2·1) |
| Previously treated tuberculosis cases | 220, 8·6% (5·0–12·3) | 196, 9·2% (5·1–13·3) | 55, 38·8% (26·2–51·4) | 202, 15·1% (10·0–20·3) | 153, 0·8% (0·0–2·5) | 125, 2·0% (0·0–4·2) |
| All tuberculosis cases | 748, 5·0% (3·4–6·6) | 933, 5·5% (3·7–7·3) | 196, 16·6% (11·4–21·9) | 1503, 11·8% (8·7–14·9) | 960, 1·0% (0·0–1·8) | 675, 1·3% (0·4–2·2) |
| Rifampicin susceptible | 618, 0·7% (0·0–1·3) | 873, 4·6% (3·0–6·2) | 99, 2·9% (0·0–6·3) | 1401, 11·1% (7·8–14·3) | 919, 0·4% (0·0–0·9) | 637, 0·2% (0·0–0·7) |
| Rifampicin resistant | 130, 25·0% (17·6–32·4) | 60, 16·0% (6·3–25·7) | 97, 30·7% (21·5–40·0) | 102, 21·8% (13·1–30·5) | 41, 12·3% (1·5–23·2) | 33, 18·3% (5·7–31·0) |
| Resistance in rifampicin resistant vs rifampicin susceptible | <0·0001 | 0·001 | <0·0001 | 0·009 | <0·0001 | <0·0001 |
| Resistance in newly vs previously treated | 0·004 | 0·014 | <0·0001 | 0·186 | 0·868 | 0·383 |
Data are number tested, % resistant (95% CI) or p value.